Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 10 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Pretreatment Serum GDF-15 and Features of Clinical Vulnerability in Advanced Pancreatic Ductal Adenocarcinoma

  • Ji Hyun Lee1
  • Kabsoo Shin2,3
  • Tae Ho Hong4
  • In-Ho Kim2,3
  • Sook-Hee Hong2,3
  • MyungAh Lee2,3
  • Se Jun Park2,3
4 affiliations
  1. 1Division of Medical Oncology, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Republic of Korea
  2. 2Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
  3. 3Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
  4. 4Department of General Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
Read full textPDFDOICite

Abstract

Background: This study aimed to define the clinical significance of pretreatment serum growth differentiation factor-15 (GDF-15), including its associations with clinical vulnerability, survival, and chemotherapy outcomes in advanced pancreatic ductal adenocarcinoma (PDAC). Methods: Pretreatment serum samples were prospectively collected from 80 patients with locally advanced or metastatic PDAC. GDF-15 was measured using an enzyme-linked immunosorbent assay and analyzed continuously and according to the cohort median. Associations with clinicopathological characteristics and overall survival (OS) were evaluated in the overall cohort. Treatment effectiveness, delivery, and safety were additionally assessed among 68 patients who received systemic chemotherapy. Results: The median GDF-15 concentration was 362.6 pg/mL. Higher GDF-15 was associated with poor performance status, involvement of multiple metastatic organ sites, an elevated neutrophil-to-lymphocyte ratio, and hypoalbuminemia. Eleven of the 12 patients unable to receive chemotherapy because of clinical deterioration had high GDF-15. The high GDF-15 group had shorter OS than the low GDF-15 group in the overall cohort (median, 6.1 vs. 13.9 months; hazard ratio [HR] = 1.96; 95% CI, 1.23–3.13; p = 0.002). The association between continuous GDF-15 and OS was attenuated and no longer statistically significant after multivariable adjustment (HR per doubling = 1.22; 95% CI, 0.97–1.52; p = 0.085). Among treated patients, progression-free survival and objective response did not differ significantly between groups, whereas high GDF-15 was associated with shorter OS (median, 8.7 vs. 14.2 months; HR = 1.72; 95% CI, 1.02–2.90; p = 0.025) and treatment duration (median, 3.2 vs. 6.3 months; p = 0.007). Relative dose intensity and subsequent treatment rates were similar. Febrile neutropenia occurred exclusively in the high GDF-15 group, which also accounted for four of five treatment-related deaths. Conclusions: Elevated pretreatment GDF-15 was associated with limited treatment fitness and inferior survival in patients with advanced PDAC, without clear evidence of intrinsic chemotherapy resistance. GDF-15 may represent a potential marker of systemic vulnerability in advanced PDAC, although its clinical utility requires external validation.

Related

  1. Immunohistochemical Expression of M30, BCL-2, BAX, and Ki-67 in Pancreatic Ductal Adenocarcinoma: Association with Clinicopathological Features
    Betül Demirciler Yavaş, Sezgin Yılmaz
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Selective AUTAC‐mediated ATP7B degradation unlocks cuproptosis vulnerability in pancreatic ductal adenocarcinoma
    Zihan Zhang, Min Li, Jiale Feng +2
    Clinical and Translational MedicinePeer-reviewedCC BY 4.0Full textEpidemiology & public healthPMC
  3. SPP1-associated pathomics features for prognostic modeling in pancreatic ductal adenocarcinoma
    Jinming Zhao, Mingjun Li, Jialiang Xing +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  4. Machine learning models integrating 2D and 3D intratumoral heterogeneity features from multi-sequence MRI: accurate prediction of perineural invasion in pancreatic ductal adenocarcinoma
    Zhiqiang Ouyang, Zhengrui Song, Zhilin Li +9
    Frontiers in artificial intelligencePeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMCPMC
  5. Non-Invasive Assessment of SMAD4 Expression Status in Pancreatic Ductal Adenocarcinoma: Diagnostic Value of T1ρ-Weighted Imaging Combined with Clinical Parameters
    Ke Li, Rui Guo, Jing Li +5
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{lee2026pretreatment,
  title = {{Pretreatment Serum GDF-15 and Features of Clinical Vulnerability in Advanced Pancreatic Ductal Adenocarcinoma}},
  author = {Ji Hyun Lee and Kabsoo Shin and Tae Ho Hong and In-Ho Kim and Sook-Hee Hong and MyungAh Lee and Se Jun Park},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15207789},
  url = {https://www.mdpi.com/2077-0383/15/20/7789},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Pretreatment Serum GDF-15 and Features of Clinical Vulnerability in Advanced Pancreatic Ductal Adenocarcinoma
AU  - Ji Hyun Lee
AU  - Kabsoo Shin
AU  - Tae Ho Hong
AU  - In-Ho Kim
AU  - Sook-Hee Hong
AU  - MyungAh Lee
AU  - Se Jun Park
PY  - 2026
DA  - 2026/10/01
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15207789
UR  - https://www.mdpi.com/2077-0383/15/20/7789
AB  - Background: This study aimed to define the clinical significance of pretreatment serum growth differentiation factor-15 (GDF-15), including its associations with clinical vulnerability, survival, and chemotherapy outcomes in advanced pancreatic ductal adenocarcinoma (PDAC). Methods: Pretreatment serum samples were prospectively collected from 80 patients with locally advanced or metastatic PDAC. GDF-15 was measured using an enzyme-linked immunosorbent assay and analyzed continuously and according to the cohort median. Associations with clinicopathological characteristics and overall survival (OS) were evaluated in the overall cohort. Treatment effectiveness, delivery, and safety were additionally assessed among 68 patients who received systemic chemotherapy. Results: The median GDF-15 concentration was 362.6 pg/mL. Higher GDF-15 was associated with poor performance status, involvement of multiple metastatic organ sites, an elevated neutrophil-to-lymphocyte ratio, and hypoalbuminemia. Eleven of the 12 patients unable to receive chemotherapy because of clinical deterioration had high GDF-15. The high GDF-15 group had shorter OS than the low GDF-15 group in the overall cohort (median, 6.1 vs. 13.9 months; hazard ratio [HR] = 1.96; 95% CI, 1.23–3.13; p = 0.002). The association between continuous GDF-15 and OS was attenuated and no longer statistically significant after multivariable adjustment (HR per doubling = 1.22; 95% CI, 0.97–1.52; p = 0.085). Among treated patients, progression-free survival and objective response did not differ significantly between groups, whereas high GDF-15 was associated with shorter OS (median, 8.7 vs. 14.2 months; HR = 1.72; 95% CI, 1.02–2.90; p = 0.025) and treatment duration (median, 3.2 vs. 6.3 months; p = 0.007). Relative dose intensity and subsequent treatment rates were similar. Febrile neutropenia occurred exclusively in the high GDF-15 group, which also accounted for four of five treatment-related deaths. Conclusions: Elevated pretreatment GDF-15 was associated with limited treatment fitness and inferior survival in patients with advanced PDAC, without clear evidence of intrinsic chemotherapy resistance. GDF-15 may represent a potential marker of systemic vulnerability in advanced PDAC, although its clinical utility requires external validation.
SN  - 2077-0383
ER  -